Long-term follow-up for patients who received CAR T-cell therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather long-term safety data on participants who received an allogeneic chimeric antigen receptor (CAR) T-cell product, specifically azer-cel, in a previous clinical study by Imugene. Participants will attend yearly visits for up to 15 years to monitor clinically significant events, response duration, and overall survival. The study does not involve administering azer-cel but allows for standard care or other investigational treatments. The focus is on understanding the long-term effects and outcomes of the CAR T-cell therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Receipt of at least 1 dose of azer-cel in an Imugene clinical study.
* A signed informed consent form (ICF).
* Willingness and ability to adhere to the study schedule and all other protocol requirements.

Exclusion Criteria:

* No unique exclusion criteria apply to this study.

Where it's running

• Science 37, Inc.
  Culver City, California, United States Recruiting

Study contacts

• Study coordinator: Clinical Imugene Limited
• Email: info@imugene.com
• Phone: 1 984 245 0082

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CAR-T Therapy Safety, Response, and Immune-Escape: Observational Study in Adults

  This observational study looks at adults who receive CAR-T cell therapy or bispecific antibodies to see which factors predict response and immune-related side effects.

  Recruiting IRCCS San Raffaele · Milan, Italy · NCT07915102

• Natalizumab to help prevent brain-related side effects during CAR-T therapy in certain lymphoma patients

  This phase 2 study tests whether natalizumab can reduce severe ICANS in adults with recurrent or refractory DLBCL or MCL receiving CAR-T therapy.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07892027

• CD19 CAR-T Therapy for Kids with Refractory Childhood SLE

  This study tests whether a patient’s own CD19 CAR-T cells can help children and young adults with severe, hard-to-treat lupus.

  Recruiting Phase 1 Seoul National University Hospital · Seoul · NCT07855302

• In vivo circular RNA CAR T cell therapy for adults with relapsed or refractory B-cell lymphomas

  A one-arm, dose-escalation study tests a circular RNA CAR T cell therapy in adults with relapsed or refractory CD19-positive B-cell cancers to see if it is safe and tolerable and to get early signs of benefit.

  Recruiting Phase 1 Ruijin Hospital · Shanghai, Shanghai Municipality and 1 other locations · NCT07774572

• CAR-T Cell Therapy for B-ALL (relapsed/refractory)

  This trial tests a patient’s own CAR-T cells to treat relapsed or refractory B-cell ALL in people aged 5–50.

  Recruiting Early Phase 1 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Rawalpindi · NCT07695012

• IgPro20 in adults with immune deficiencies after CAR T-cell or T-cell redirecting therapies

  This study tests IgPro20 in adults with secondary immune deficiency after CAR T-cell or T-cell redirecting therapies to see if it lowers serious bacterial infections.

  Recruiting at 2 sites Phase 3 CSL Behring · Orange, California and 59 other locations · NCT07648264

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.